FLT3-Mutated High-Risk Myelodysplastic Syndrome
1 clinical trials · Condition
◉ Watch FLT3-Mutated High-Risk Myelodysplastic Syndrome
| Record | Firm | Date |
|---|---|---|
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) (NCT02829840) | M.D. Anderson Cancer Center | 2016-09-01 |
Track FLT3-Mutated High-Risk Myelodysplastic Syndrome automatically
Every clearance here is in the API, with alerts when new ones post.